| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
7-Deaza-2'-deoxy-7-iodoadenosine does not have a specific biological target as a therapeutic agent itself but serves as a modified nucleoside building block for oligonucleotide synthesis. When incorporated into oligonucleotides, the 7-deaza modification can alter base pairing properties, increase nuclease resistance, and modulate interactions with proteins such as polymerases and nucleases. The iodine substituent enables further functionalization through cross-coupling reactions, allowing the introduction of various chemical groups for applications in nucleic acid labeling and therapeutic development.
|
|---|---|
| ln Vitro |
In vitro activity of 7-Deaza-2'-deoxy-7-iodoadenosine is assessed by its incorporation efficiency into oligonucleotides during solid-phase synthesis. The resulting modified oligonucleotides are evaluated for their binding affinity to complementary nucleic acid targets using thermal melting (Tm) analysis. Nuclease resistance is assessed by incubation with various nucleases (e.g., snake venom phosphodiesterase, S1 nuclease) followed by gel electrophoresis or HPLC analysis. The compound's ability to support polymerase-mediated synthesis is evaluated using primer extension assays with various DNA and RNA polymerases.
|
| ln Vivo |
In vivo studies for 7-Deaza-2'-deoxy-7-iodoadenosine are typically conducted on the modified oligonucleotides incorporating this nucleoside rather than the monomer itself. These oligonucleotides are evaluated in animal models for their pharmacokinetic properties, biodistribution, and therapeutic efficacy in applications such as antisense therapy, siRNA, or aptamer development. The 7-deaza modification can enhance metabolic stability and reduce immunogenicity of therapeutic oligonucleotides, potentially improving their in vivo performance.
|
| Enzyme Assay |
For oligonucleotide synthesis, 7-Deaza-2'-deoxy-7-iodoadenosine is converted to the corresponding phosphoramidite and incorporated into oligonucleotides using standard solid-phase synthesis protocols. Coupling efficiency is monitored by trityl cation release measurements. For base pairing studies, modified and unmodified oligonucleotides are hybridized to complementary strands, and thermal melting curves are recorded at 260 nm using a UV-Vis spectrophotometer with a temperature ramp of 0.5-1°C/min. Nuclease stability is assessed by incubating oligonucleotides with nuclease solutions at 37°C and analyzing degradation products by PAGE or HPLC.
|
| Cell Assay |
For cellular uptake and activity studies, cultured cells are treated with modified oligonucleotides containing 7-Deaza-2'-deoxy-7-iodoadenosine. Cells are incubated with oligonucleotides for 24-72 hours, and cellular uptake is assessed by fluorescence microscopy or flow cytometry using fluorescently labeled oligonucleotides. Gene knockdown efficiency is evaluated by qRT-PCR or Western blot for antisense or siRNA applications. Cytotoxicity is assessed using MTT or CellTiter-Glo assays. For functionalization studies, the iodine group is used for palladium-catalyzed cross-coupling reactions to introduce various labels or functional groups.
|
| Animal Protocol |
For in vivo evaluation of modified oligonucleotides, mice or rats are administered the oligonucleotides via intravenous, subcutaneous, or intraperitoneal injection. Pharmacokinetic parameters including half-life, clearance, and tissue distribution are determined by measuring oligonucleotide concentrations in plasma and tissues using hybridization-based assays or LC-MS. For therapeutic applications, efficacy is evaluated in appropriate disease models (e.g., tumor xenografts for antisense therapy), with tumor volume or disease biomarkers monitored over time.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 7-Deaza-2'-deoxy-7-iodoadenosine are typically characterized for the modified oligonucleotides incorporating this nucleoside. The 7-deaza modification can increase metabolic stability by reducing susceptibility to nuclease degradation. The compound is soluble in DMSO at 50 mg/mL (132.93 mM). Detailed PK parameters depend on the specific oligonucleotide sequence, length, and backbone chemistry. The iodine substituent may affect the compound's lipophilicity and cellular uptake properties.
|
| Toxicity/Toxicokinetics |
7-Deaza-2'-deoxy-7-iodoadenosine is a research compound intended for laboratory use only and is not approved for human therapeutic use. As a modified nucleoside, it is used in the synthesis of oligonucleotides with enhanced properties for therapeutic and diagnostic applications. The compound should be handled with standard laboratory safety precautions. Toxicity studies are typically conducted on the complete modified oligonucleotides rather than the nucleoside monomer. The compound is stable when stored as recommended.
|
| References | |
| Additional Infomation |
7-Deaza-2'-deoxy-7-iodoadenosine is a modified nucleoside analog containing 7-deazaadenine, with molecular formula C11H13IN4O3 and molecular weight 376.15. It is used as a building block in oligonucleotide synthesis for applications in nucleic acid therapeutics, diagnostics, and structural studies. The 7-deaza modification alters base pairing properties and increases nuclease resistance, while the iodine substituent enables further functionalization. The compound is soluble in DMSO at 50 mg/mL. It is for research use only and has not been approved for clinical applications.
|
| Molecular Formula |
C11H13IN4O3
|
|---|---|
| Molecular Weight |
376.15
|
| Exact Mass |
376.003
|
| CAS # |
166247-63-8
|
| Related CAS # |
(2S,3R,5S)-7-Deaza-2'-deoxy-7-iodoadenosine;908130-61-0
|
| PubChem CID |
15289165
|
| Appearance |
White to off-white solid powder
|
| Density |
2.4±0.1 g/cm3
|
| Boiling Point |
657.4±55.0 °C at 760 mmHg
|
| Flash Point |
351.4±31.5 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.882
|
| LogP |
0.97
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
337
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1[C@@H]([C@H](O[C@H]1N2C=C(C3=C(N=CN=C32)N)I)CO)O
|
| InChi Key |
LIIIRHQRQZIIRT-XLPZGREQSA-N
|
| InChi Code |
InChI=1S/C11H13IN4O3/c12-5-2-16(8-1-6(18)7(3-17)19-8)11-9(5)10(13)14-4-15-11/h2,4,6-8,17-18H,1,3H2,(H2,13,14,15)/t6-,7+,8+/m0/s1
|
| Chemical Name |
(2R,3S,5R)-5-(4-amino-5-iodopyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)oxolan-3-ol
|
| Synonyms |
7-Deaza-2'-deoxy-7-iodoadenosine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~132.9 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.65 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6585 mL | 13.2926 mL | 26.5851 mL | |
| 5 mM | 0.5317 mL | 2.6585 mL | 5.3170 mL | |
| 10 mM | 0.2659 mL | 1.3293 mL | 2.6585 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
